Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Richard Conway RichardPAConway
3 years 1 month ago
Kirby @colmkirby22 et al. US monitoring in newly diagnosed GCA. US mirrored clinical activity and predicted need for tocilizumab use. @rheumnow #ACR22 Abstr#0479 https://t.co/Ncqi8rZI6K https://t.co/DmzhNyzEfI
Aurelie Najm AurelieRheumo
3 years 1 month ago
How age influence PsA clinical phenotype and diag?
Late onset PsA associated w/ male, > damage, > arthritis, > BASFI, < diag delay and < SI and enthesitis reports Puche-Larrubia et al from RESPONDIA & REGISPONSER registries.
https://t.co/pC21Yv8Nv9
Abstr #0377 #ACR22 @Rheumnow https://t.co/cQRDELO5my
Julian Segan JulianSegan
3 years 1 month ago
Complement TRENDS rather than absolute numbers may be more useful in pregnancy
@RheumNow #ACR22 #Pearls https://t.co/jz2SzdClfs
Richard Conway RichardPAConway
3 years 1 month ago
Koc et al Female RA patients improve less in terms of disease activity over time. Score worse on HAQ,fatigue,SF-36 PCS, and morning stiffness duration @rheumnow #ACR22 Abstr#241 https://t.co/5HA0m3hNG4 https://t.co/Dx3C9r7FTl
Aurelie Najm AurelieRheumo
3 years 1 month ago
@DiegoBenavent et al: Gender impacts disease outcomes in PsA and SpA. Women > BASDAI, >BASFI, > ASDAS, >ASDAS Hi, and > EQ-5D.
Not so surprising considering higher ratio for Fibromyalgia in W
ASDAS not asso w/ gender in AxSPA.
https://t.co/kBxvAi5qZw
Abstr #0381 #ACR22 @Rheumnow https://t.co/vxdtlKpT3l
David Liew drdavidliew
3 years 1 month ago
We've never been convinced on adjunct therapy in GCA - yet we're still worried about aortic dilatation.
Beta-blockers we're def not doing - but impressive retrospective data here.
Let's test this properly!
ABST0477 #ACR22 @RheumNow
(also @seminarthrheum https://t.co/onKW2JKIzo) https://t.co/yHTx29NJNX
Dr. Rachel Tate uptoTate
3 years 1 month ago
Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089
Continued under-reporting of race and ethnicity in PsA trials. Abs 0090
We can do better #rheumtwitter
#ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg
Bella Mehta bella_mehta
3 years 1 month ago
Germany based 74 pt #FMF prospective non-interventional, multicenter observational study on Canakinumab - RELIANCE Registry
63% in remission in 2 yrs
serious adverse drug reactions - 1.56 per 100 patient years
@RheumNow #ACR22 abst#0138
Dr. Rachel Tate uptoTate
3 years 1 month ago
@ericdeinmd is moderating a great session, difficult to treat RA at #ACR22 right now! #rheumpix @RheumNow https://t.co/R5yg3eme6v
Dr. John Cush RheumNow
3 years 1 month ago
Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/y7VWk3lOXD
Richard Conway RichardPAConway
3 years 1 month ago
Culerrier @AKronbichler @TerrierBen et al. AAV induced by anti-thyroid drugs. 45 cases. vs AAV - younger (45 vs 68) More skin (54 vs 25%) Less renal (38 vs 73%) Less severe (BVAS 9 vs 13) Less relapse (HR 0.07). Can rechallenge! @rheumnow #ACR22 Abstr#0436 https://t.co/0i7zj615N6 https://t.co/t7fWCOuUsJ
Janet Pope Janetbirdope
3 years 1 month ago
OPAL data is a gem! Large Australian data studying JAKi use in #rheumatoidarthritis N=5900 Switching JAKi~JAKi-common. As in TNFi 1st line Rx had longer retention & better efficacy than 2nd & subsequent. Median 1st advanced Rx - same in all JAKs 34 MOA @RheumNow #ACR22 abst0274 https://t.co/FQU4AKXwe9
Richard Conway RichardPAConway
3 years 1 month ago
Dey @DrMiniDey @ElenaNikiUK @docrota @LatikaGupta_ et al. COVID vaccination in IIM+multimorbidity. Adverse events more common, but still infrequent. Both multimorbidity and active IIM increased risk of AEs. @rheumnow #ACR22 Abstr#0177 https://t.co/HA5NaRrPYL https://t.co/TKtagwa0gG
Eric Dein ericdeinmd
3 years 1 month ago
Coming soon on #ACR22:
Stream session 12S119 on @ACRheum and @ACRheumDC advocacy
What is new on the Hill?
What are ACR priorities
How quickly can you send an email supporting rheumatologists (quicker than you think!)
@RheumNow
@AngusWorthing @BlairSolowM @LennMcD @LouisaZiglar https://t.co/sXSBGbCZyM
Richard Conway RichardPAConway
3 years 1 month ago
Froehlich et al. MRI superior to US in GCA. For all GCA sensitivity 73% vs 45%. For supra-aortic GCA sensitivity 73% vs 59%. Both 100% specificity. @rheumnow #ACR22 Abstr#0493 https://t.co/vf2r0h5zUd https://t.co/mlSCcpy2uK
Poster Hall